Dimensional Fund Advisors’s TScan Therapeutics TCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64K	Hold	65,335	–	–	﹤0.01%	3178
2026 Q1	$65.8K	Sell	65,335 -9,132	-12%	-$9.76K	﹤0.01%	3156
2025 Q4	$74.5K	Sell	74,467 -12,849	-15%	-$18.6K	﹤0.01%	3184
2025 Q3	$159K	Sell	87,316 -42,540	-33%	-$75.4K	﹤0.01%	3148
2025 Q2	$188K	Sell	129,856 -140,243	-52%	-$203K	﹤0.01%	3123
2025 Q1	$373K	Sell	270,099 -9,929	-4%	-$21.5K	﹤0.01%	3038
2024 Q4	$851K	Buy	280,028 +145,731	+109%	+$661K	﹤0.01%	2949
2024 Q3	$669K	Buy	134,297 +122,415	+1,030%	+$739K	﹤0.01%	2980
2024 Q2	$70.5K	Buy	+11,882	New	+$93.6K	﹤0.01%	3284

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Dimensional Fund Advisors's TCRX Position: Q2 2026 in Review

Dimensional Fund Advisors held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 65,335 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Dimensional Fund Advisors first reported a position in TCRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $851K in Q4 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Dimensional Fund Advisors held 65,335 shares of TScan Therapeutics worth $64K as of Q2 2026.
Dimensional Fund Advisors left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3178 holding.
Dimensional Fund Advisors first reported a position in TScan Therapeutics in Q2 2024 and has held it in 9 quarters since.
Dimensional Fund Advisors's TScan Therapeutics position peaked at $851K in Q4 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.